XML 86 R66.htm IDEA: XBRL DOCUMENT v3.25.1
Segment Reporting (Details)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
USD ($)
performanceObligation
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]      
Number of Reportable Segments | performanceObligation 1    
Revenues $ 149,962 $ 58,749 $ 151,941
Cost of product sales 847 619 3,351
Cost of manufacturing services 11,452 7,603 4,033
Research and development 177,194 166,583 207,026
Selling, general and administrative 71,047 52,188 58,949
Net loss (66,966) (9,058) (119,758)
Main Segment      
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]      
Segment Reporting, Other Segment Item, Amount 43,612 159,186 1,660
Main Segment | Vobramitanmab duocarmazine [Member]      
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]      
Research and development 39,809 39,217 55,381
Main Segment | Lorigerlimab      
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]      
Research and development 36,805 27,716 21,581
Main Segment | MGC028      
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]      
Research and development 24,055 14,408 0
Main Segment | ADC      
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]      
Research and development 18,102 11,170 12,975
Main Segment | MGC026      
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]      
Research and development 14,126 13,523 5,287
Main Segment | Margetuximab      
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]      
Research and development 10,846 16,081 26,869
Main Segment | MGD024      
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]      
Research and development 9,734 6,974 7,857
Main Segment | Next-generation T-cell engagers      
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]      
Research and development 8,421 10,464 13,335
Main Segment | Retifanlimab      
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]      
Research and development 2,129 3,452 2,156
Main Segment | Enoblituzumab      
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]      
Research and development 1,906 5,344 14,725
Main Segment | Other programs      
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]      
Research and development $ 11,261 $ 18,234 $ 46,860